JV
Therapeutic Areas
Acrivon Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ACR-368 (prexasertib) | Multiple high unmet need solid cancer types (ovarian, endometrial, head and neck squamous cell carcinoma) | Phase 2 |
| ACR-2316 | Not specified (likely solid tumors) | Clinical candidate |
| ACR-6840 | Not specified (likely solid tumors) | Development candidate |
Leadership Team at Acrivon Therapeutics
PB
Peter Blume-Jensen
CEO, President, Founder, Chairperson
AD
Adam D. Levy
Chief Financial Officer
MR
Mansoor Raza Mirza
Chief Medical Officer
EG
Erick Gamelin
Chief Development Officer
KM
Kristina Masson
Co-Founder, EVP, Business Operations, Site Head, Director
JO
Jesper Olsen
Academic Co-Founder, Head of Phosphoproteomics
ED
Eric Devroe
Chief Operating Officer
MS
Michail Shipitsin
Head of Biomarker Development
JJ
Joon Jung
Head of Data Science